Giants of Cancer Care® Program Inductees
Gastrointestinal Cancer
Eileen M. O’Reilly, MD
Memorial Sloan Kettering Cancer Center
- O’Reilly is the Winthrop Rockefeller Endowed Chair of Medical Oncology, section head, Hepatopancreaticobiliary & Neuroendocrine Cancers, and codirector, medical initiatives, of the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center.
- She has been the principal investigator of numerous phase 1, 2, and 3 clinical studies in pancreatic cancer and specializes in targeted, neoadjuvant, and adjuvant therapeutics for the malignancy.
- One of O’Reilly’s notable clinical trial involvements includes a coauthorship for the Cancer and Leukemia Group B 80303 trial (NCT00088894), which showed that the addition of bevacizumab (Avastin) to gemcitabine did not improve survival compared with gemcitabine monotherapy in patients with advanced pancreatic cancer.
- She was a coauthor of findings from the phase 3 POLO trial (NCT02184195), which demonstrated that maintenance olaparib (Lynparza) improved outcomes vs placebo in patients with germline BRCA–mutant metastatic pancreatic cancer that has not progressed after first-line platinum-based chemotherapy. The agent was approved in 2019 for this indication.
- O’Reilly is cochair of the National Cancer Institute (NCI) Alliance Co-Operative Group Gastrointestinal Cancers Committee and a member of the NCI Gastrointestinal Cancers Steering Committee.
- She also serves on the medical and scientific advisory board of the Pancreatic Cancer Action Network, the National Comprehensive Cancer Network Pancreas Panel, the American Society of Clinical Oncology Guidelines Committee, and the scientific board of the National Pancreas Foundation. O’Reilly also coauthored the book “100 Questions and Answers About Pancreatic Cancer.”
Home
SUPPORTED BY
